-
Media ReleaseNovartis therapy Gilenya™ reduced the risk of MS disability progression regardless of treatment history or disease severity, new analysis shows
-
Media ReleaseFDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD
-
Media ReleaseImportant Information for Extavia® (interferon beta 1-b) Patients Regarding Triad Group's Alcohol Prep Products
-
Media ReleaseNovartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
-
Media ReleaseLonger-term Phase III data show Novartis drug Tasigna® continues to surpass Gleevec® in slowing disease progression in patients with newly diagnosed CML
-
Media ReleaseNovartis Pharmaceuticals Corporation restructuring US field force to align with changing product portfolio and strategic growth priorities
-
Media ReleaseNew “Stand Together for AD” campaign provides strength, support and important resources for 11 million Alzheimer’s caregivers
-
Media ReleaseAnalysis shows Novartis drug TOBI® associated with reduced mortality in cystic fibrosis patients with common lung infection
-
Media ReleaseNovartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
-
Media ReleaseNovartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
-
Media ReleaseUS Affiliate of Novartis Strongly Disputes Claims of Past Discrimination in the US
-
Media ReleaseNovartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court